Can you take colchicine after gastric sleeve surgery? This is an important question for patients managing gout, familial Mediterranean fever, or pericarditis following bariatric surgery. Sleeve gastrectomy significantly reduces stomach volume and alters gastric emptying, raising legitimate concerns about how oral medications are absorbed. Colchicine has a narrow therapeutic index, meaning small changes in absorption or drug interactions can have serious consequences. This article explores what the evidence shows about colchicine use after gastric sleeve surgery, including absorption, risks, dosing guidance, and when to seek advice from your GP or bariatric team.

How Gastric Sleeve Surgery Affects Medication Absorption

Sleeve gastrectomy reduces gastric volume by 75–80% and accelerates gastric emptying, but preserves the full intestinal tract, meaning intestinal drug absorption remains largely intact unlike malabsorptive bypass procedures.

Sleeve gastrectomy, commonly known as gastric sleeve surgery, involves the surgical removal of approximately 75–80% of the stomach, leaving a narrow, tube-shaped gastric remnant. This anatomical change has significant implications not only for nutrition and weight management, but also for how the body absorbs oral medications. Understanding these changes is essential before considering any long-term drug therapy post-operatively.

The stomach plays a critical role in the early stages of drug absorption. It provides an environment that aids in the dissolution of many tablet formulations, and its muscular contractions help break down solid dosage forms before they pass into the small intestine. Following a sleeve gastrectomy, gastric volume is dramatically reduced and gastric emptying is accelerated. Gastric pH may also be altered — some patients experience increased gastric acid reflux (GORD), whilst others may have reduced acid output — and this variability can affect the dissolution and absorption of certain medicines. These changes can affect the rate and extent of drug absorption.

Key pharmacokinetic changes observed after gastric sleeve surgery include:

• Faster gastric emptying, which may reduce the time a drug spends in the stomach and alter its dissolution profile

• Altered gastric pH, which is variable between individuals and may affect drugs that are pH-sensitive

• Unpredictable behaviour of modified-release or enteric-coated formulations, which may release drug at the wrong site or at an unpredictable rate; immediate-release formulations are generally preferred post-bariatric surgery

Importantly, unlike Roux-en-Y gastric bypass — which bypasses a significant portion of the small intestine — sleeve gastrectomy preserves the full length of the intestinal tract. This means that intestinal absorption remains largely intact, which is a clinically relevant distinction when assessing medication suitability after surgery.

UK guidance from the Specialist Pharmacy Service (SPS) and the British Obesity and Metabolic Surgery Society (BOMSS) recommends that medicines use after bariatric surgery is reviewed on an individual basis, with preference given to immediate-release formulations where possible and with ongoing monitoring of clinical response.

Colchicine After Bariatric Surgery: What the Evidence Shows

Colchicine is absorbed in the small intestine, which is anatomically preserved after sleeve gastrectomy, suggesting absorption is broadly maintained, though individual variation and clinical monitoring remain essential.

Colchicine is a well-established anti-inflammatory agent used in the UK for the management of gout and familial Mediterranean fever (FMF). It is also used for pericarditis, although this indication is off-label in the UK and should be initiated and supervised by a specialist. Colchicine works by binding to tubulin, thereby inhibiting microtubule polymerisation and disrupting neutrophil migration and activation — the key inflammatory processes responsible for the acute pain and swelling associated with these conditions. Given its narrow therapeutic index and specific absorption characteristics, its use following bariatric surgery warrants careful consideration.

Based on the UK Summary of Product Characteristics (SmPC) and BNF monograph, colchicine is absorbed in the small intestine, with peak plasma concentrations typically reached within one to two hours of oral administration. Because sleeve gastrectomy does not bypass or resect any portion of the small intestine, the primary site of colchicine absorption remains anatomically intact. This is an important distinction from malabsorptive procedures such as Roux-en-Y gastric bypass, where intestinal rerouting can significantly reduce drug bioavailability.

There is currently limited high-quality, procedure-specific clinical trial data examining colchicine pharmacokinetics exclusively in sleeve gastrectomy patients. Based on the preserved intestinal anatomy, absorption is likely to be broadly maintained after sleeve gastrectomy; however, individual variation exists and clinical response and tolerability should be monitored carefully. The absence of a formal contraindication in the MHRA-approved SmPC does not eliminate the need for clinical oversight, particularly given colchicine's narrow therapeutic window and potential for serious toxicity at elevated plasma concentrations.

Patients and clinicians should be aware that:

• For gout and FMF, colchicine is a licensed indication in the UK; dosing should follow current NICE NG219 and BNF guidance

• For pericarditis, colchicine use is off-label in the UK and should be initiated under specialist supervision (e.g., cardiology), in line with NICE CKS guidance on pericarditis

• Any concerns about efficacy or tolerability post-surgery should be discussed promptly with the prescribing clinician or bariatric team

Risks and Considerations for Post-Sleeve Patients

Key risks include worsened gastrointestinal side effects, serious drug interactions via CYP3A4 and P-glycoprotein inhibition, and the need for dose adjustment in renal or hepatic impairment.

Whilst colchicine absorption is likely to be broadly preserved after sleeve gastrectomy, there are several important risks and clinical considerations that patients and healthcare professionals should be aware of before initiating or continuing therapy.

Gastrointestinal side effects are among the most common adverse effects of colchicine and include nausea, vomiting, abdominal cramping, and diarrhoea. These effects are dose-dependent and can be particularly problematic in post-sleeve patients, who already have a reduced gastric capacity and may be more sensitive to gastrointestinal disturbance. Diarrhoea, in particular, can exacerbate the risk of dehydration and electrolyte imbalance — concerns that are already heightened in the bariatric population. If severe vomiting or diarrhoea occurs, colchicine should be stopped and urgent medical advice sought.

Post-bariatric patients are at increased risk of nutritional deficiencies, including deficiencies in vitamin B12, folate, iron, and fat-soluble vitamins. Regular monitoring of nutritional status is particularly important in this population, and any new symptoms should be reported to the clinical team.

Drug interactions are a major safety concern with colchicine. It is metabolised by CYP3A4 and is a substrate of P-glycoprotein (P-gp). According to the MHRA-approved SmPC, co-administration with strong CYP3A4 or P-gp inhibitors — particularly in patients with renal or hepatic impairment — can cause life-threatening or fatal colchicine toxicity. Medicines that significantly increase colchicine plasma levels include:

• Macrolide antibiotics (e.g., clarithromycin, erythromycin)

• Azole antifungals (e.g., ketoconazole, itraconazole)

• HIV protease inhibitors

• Ciclosporin

• Verapamil and diltiazem

• Grapefruit juice (CYP3A4 inhibition; patients should avoid grapefruit juice whilst taking colchicine)

Additionally, concurrent use of statins or fibrates increases the risk of myopathy and should be used with caution alongside colchicine (BNF).

Other important considerations include:

• Renal and hepatic function: Colchicine undergoes CYP3A4 hepatic metabolism and is eliminated via both biliary and renal routes. Dose reduction or avoidance is required in patients with significant renal or hepatic impairment — relevant to some post-bariatric patients with comorbidities. Refer to the BNF and SmPC for specific dose adjustment guidance

• Accelerated gastric emptying: Faster transit may theoretically affect dissolution of tablet formulations, though this is less likely to be clinically significant given intestinal absorption is preserved

Patients should be counselled to report any new or worsening symptoms promptly, and to check with their prescriber or pharmacist before starting any new medicine — particularly macrolide antibiotics or azole antifungals — whilst taking colchicine.

Suspected adverse drug reactions should be reported via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Practical Guidance on Dosing and Administration

Immediate-release colchicine 500 microgram tablets are preferred post-sleeve; dosing follows NICE NG219 and BNF guidance, with renal and hepatic function assessed before initiation and interactions reviewed.

For patients who have undergone sleeve gastrectomy and require colchicine therapy, practical guidance on dosing and formulation choice can help optimise both safety and efficacy. Any prescribing decisions should be made in collaboration with the patient's GP, bariatric team, and, where appropriate, a specialist such as a rheumatologist or cardiologist.

Formulation availability in the UK: Colchicine is available in the UK as immediate-release 500 microgram tablets. Modified-release colchicine products are not standard in the UK. Liquid (oral solution) formulations are not routinely licensed in the UK and are typically prepared as unlicensed 'specials' by a specialist pharmacy; if a liquid preparation is required (for example, due to difficulty swallowing), this must be arranged through and verified by a pharmacist, with dosing confirmed by the prescribing clinician.

Immediate-release tablets are the preferred formulation for post-bariatric patients, in line with SPS and BOMSS guidance, as modified-release or enteric-coated preparations can behave unpredictably following bariatric surgery.

Dosing principles should follow current UK guidance (NICE NG219, BNF, and MHRA-approved SmPC):

• Acute gout flare: colchicine 500 micrograms 2–4 times daily, adjusted according to response and tolerability; the maximum recommended dose per course is 6 mg — do not repeat a course within 3 days. The older high-dose regimens (e.g., 1 mg followed by 500 micrograms hourly) are no longer recommended in the UK due to greater toxicity risk

• Prophylaxis of gout flares: colchicine 500 micrograms once or twice daily (maximum 1 mg per day); dose should be reduced in renal or hepatic impairment — refer to the BNF and SmPC

• FMF and off-label indications (e.g., pericarditis): dosing should be directed by the relevant specialist and follow current clinical guidance

• Renal and hepatic function should be assessed prior to initiation and monitored periodically, with dose adjustment as indicated in the BNF and SmPC

• The full medication list should be reviewed for potential CYP3A4 or P-glycoprotein interactions before prescribing (see Risks section above)

Patients should be advised to take colchicine with adequate fluid; taking it with food may help reduce gastrointestinal side effects. Tablets should not be crushed or dispersed unless a pharmacist has confirmed this is appropriate for the specific product, as altering the tablet may affect drug delivery. Any concerns about swallowing or tolerability should be discussed with the dispensing pharmacist or prescribing clinician.

Experiencing these side effects? Our pharmacists can help you navigate them →

Patients should also be reminded to avoid grapefruit juice whilst taking colchicine.

When to Seek Advice From Your GP or Bariatric Team

Patients should consult their GP or bariatric team before starting colchicine, and seek urgent medical attention if severe vomiting, muscle weakness, dark urine, or signs of serious toxicity develop.

Patients who have had a gastric sleeve and are considering taking colchicine — whether for a new diagnosis of gout, an ongoing condition such as FMF, or for pericarditis (off-label, under specialist supervision) — should always consult their GP or bariatric team before starting or adjusting treatment. Self-medicating with colchicine without professional oversight carries real risks, particularly given its narrow therapeutic index and the physiological changes that follow bariatric surgery.

Stop colchicine and seek urgent medical attention (call 999 or go to your nearest emergency department) if you experience any of the following:

• Severe or persistent vomiting or diarrhoea, particularly with signs of dehydration (dizziness, dark urine, reduced urine output, or feeling faint)

• Profound or unexplained muscle weakness, pain, or tenderness — this may indicate myopathy or, rarely, rhabdomyolysis

• Dark or discoloured urine alongside muscle symptoms

• Confusion, difficulty breathing, or feeling very unwell

• Signs of severe infection or unusual bruising and bleeding (which may suggest bone marrow suppression — a rare but serious adverse effect)

Contact your GP promptly if you experience:

• Mild to moderate nausea, vomiting, abdominal cramping, or diarrhoea that is not resolving

• Tingling or numbness in the hands or feet (which may suggest peripheral neuropathy)

• Any new or worsening symptoms that concern you

Your bariatric team should be informed of any new medicines started after surgery, as they are best placed to assess potential interactions with your post-operative nutritional regimen and any supplements you may be taking.

Before starting any new medicine — especially macrolide antibiotics (such as clarithromycin) or azole antifungals — always check with your prescriber or pharmacist, as these can dangerously increase colchicine levels in the blood.

NICE guidance on the management of gout (NG219) emphasises the importance of coordinated, multidisciplinary care — a principle that applies directly to post-bariatric patients managing inflammatory conditions.

In summary, whilst there is no official contraindication to taking colchicine after a gastric sleeve, it is not a decision to be made without professional input. With appropriate monitoring, correct dosing, and communication between your clinical teams, colchicine can be used safely and effectively in this patient group.

If you experience a suspected side effect from colchicine, please report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or using the Yellow Card app.

Frequently Asked Questions